Eisai
Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology. Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai's reported carbon emissions
In 2023, Eisai Co., Ltd., headquartered in Japan, reported total greenhouse gas emissions of approximately 585,860,000 kg CO2e. This figure includes 48,586,000 kg CO2e from Scope 1 emissions, 2,673,000 kg CO2e from Scope 2 emissions, and a significant 563,928,000 kg CO2e from Scope 3 emissions, primarily from purchased goods and services. Eisai has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 55% by fiscal 2030, using fiscal 2019 as the base year. Additionally, the company targets a 27.5% reduction in Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to achieving net-zero emissions by 2050. In previous years, Eisai's emissions have shown fluctuations, with Scope 1 emissions recorded at 47,507,000 kg CO2e in 2022 and 46,534,000 kg CO2e in 2021. Scope 2 emissions were 6,105,000 kg CO2e in 2022 and 27,967,000 kg CO2e in 2021, while Scope 3 emissions were 602,655,000 kg CO2e in 2022 and 521,809,000 kg CO2e in 2021. Eisai's climate strategy is comprehensive, with a focus on reducing emissions across all scopes, demonstrating a proactive approach to sustainability in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
